高级检索
    蒋苏静, 谢聪颖, 卢红莲. Durvalumab治疗放化疗后Ⅲ期非小细胞肺癌患者的总生存期获益[J]. 循证医学, 2020, 20(1): 49-52. DOI: 10.12019/j.issn.1671-5144.2020.01.011
    引用本文: 蒋苏静, 谢聪颖, 卢红莲. Durvalumab治疗放化疗后Ⅲ期非小细胞肺癌患者的总生存期获益[J]. 循证医学, 2020, 20(1): 49-52. DOI: 10.12019/j.issn.1671-5144.2020.01.011
    shu
    JIANG Su-jing, XIE Cong-ying, LU Hong-lian. Overall Survival with Durvalumab after Chemoradio-therapy in Stage Ⅲ NSCLC[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 49-52. DOI: 10.12019/j.issn.1671-5144.2020.01.011
    Citation: JIANG Su-jing, XIE Cong-ying, LU Hong-lian. Overall Survival with Durvalumab after Chemoradio-therapy in Stage Ⅲ NSCLC[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 49-52. DOI: 10.12019/j.issn.1671-5144.2020.01.011
    shu

    Durvalumab治疗放化疗后Ⅲ期非小细胞肺癌患者的总生存期获益

    Overall Survival with Durvalumab after Chemoradio-therapy in Stage Ⅲ NSCLC

      摘要
      • HTML全文
      • 参考文献(11)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回